Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales
June 29, 2020 at 15:50 PM EDT
Novavax, Inc. shares are on a dream run this year amid catalysts including its COVID-19 vaccine program.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|